NCT06153173View on ClinicalTrials.gov

Mirdametinib in Histiocytic Disorders

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2031

Conditions
Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)Rosai-Dorfman Disease (RDD)Histiocytic Disorders
Interventions
DRUG

Mirdametinib

Mirdametinib is administered by mouth twice daily on a continuous schedule, with each cycle being 4 weeks. Patients are instructed to take consecutive doses separated by a minimum of 6 hours and a maximum of 14 hours.

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER